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Objective:  The  phase  III IUNO  trial assessed  the  beneﬁt  of  maintenance  erlotinib  versus  erlotinib  at
progression  in advanced/metastatic  non-small-cell  lung  cancer  (NSCLC)  that  had  not progressed  fol-
lowing  four  cycles  of  platinum-based  chemotherapy.
Materials and Methods:  Patients  had  stage  IIIB/IV  NSCLC,  no  known  epidermal  growth  factor  recep-
tor  (EGFR)-activating  mutation,  and  objective  response  or disease  stabilization  after  platinum-based
induction  chemotherapy.  Central  EGFR-mutation  testing  was  undertaken  on  tumors  from  patients  with
unknown  or wild-type  EGFR  status  following  local  testing.  Patients  were  randomized  to receive  blinded
maintenance  erlotinib  150  mg/day  (‘early  erlotinib’)  or placebo.  Those  who  progressed  on placebo
received  open-label  erlotinib  (‘late  erlotinib’);  patients  who  progressed  on  erlotinib  received  approved
second-line  chemotherapy  or  best supportive  care. Primary  endpoint:  overall  survival  (OS).
Results:  643  patients  were  randomized  to  receive  maintenance  erlotinib  (n = 322)  or placebo  (n  =  321).
As of March  23, 2015,  242  (75.2%)  OS  events  had  occurred  with  ‘early  erlotinib’  versus  235 (73.2%)  with
‘late  erlotinib’.  Median  OS  was 9.7  and  9.5 months  with  ‘early  erlotinib’  and  ‘late  erlotinib’,  respectively
(HR,  1.02,  95%  CI: 0.85–1.22;  log-rank  p =  0.82).  No  progression-free  survival,  objective  response  rate,  or
disease  control  rate  beneﬁt  was  observed  with  maintenance  erlotinib.  410  patients  entered  the  second-
line  phase  of  the  study:  160  patients  (50%)  from  the  maintenance  erlotinib  arm  and  250  patients  (78%)
from  the maintenance  placebo  arm.  The  pattern  of  adverse  events  (AEs)  was  consistent  with  previous
trials;  11  patients  who  received  blinded  erlotinib  and  3 who  received  placebo  died  during  the  blinded
maintenance  phase  due  to nontreatment-related  AEs.
Conclusions:  OS  with  maintenance  erlotinib  was not  superior  to second-line  treatment  in patients
whose  tumor  did  not  harbor  an EGFR-activating  mutation.  Safety  results  were  consistent  with  the
established  safety  proﬁle  of  erlotinib.  Thus,  maintenance  treatment  with erlotinib  in  patients  with
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1. Introduction
The tyrosine kinase inhibitor, erlotinib, is indicated for the ﬁrst-
line treatment of patients with locally advanced or metastatic
non-small-cell lung cancer (NSCLC) with epidermal growth fac-
tor receptor (EGFR)-activating mutations, for the treatment of
patients with locally advanced or metastatic NSCLC after failure
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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f at least one prior chemotherapy regimen, and in the European
nion for maintenance therapy in patients with locally advanced
r metastatic NSCLC with EGFR-activating mutations and stable
isease (SD) after ﬁrst-line chemotherapy. In the USA and other
ountries, the maintenance indication is being revised following
he outcome of the study reported here.
Approval of erlotinib in the maintenance setting for locally
dvanced or metastatic NSCLC was based on the results of the ran-
omized, multicenter, placebo-controlled phase III SATURN trial,
hich evaluated the efﬁcacy of erlotinib following four cycles of
tandard platinum-based ﬁrst-line chemotherapy in patients who
ad not experienced disease progression or unacceptable toxicity
uring chemotherapy [1]. Maintenance therapy with erlotinib was
ell tolerated and signiﬁcantly prolonged progression-free sur-
ival (PFS) compared with placebo in the SATURN trial (hazard ratio
HR] for PFS 0.71, 95% conﬁdence interval [CI]: 0.62–0.82; log-rank
 < 0.0001) that was conducted in patients who were not selected
ased on EGFR-mutation status.
Here we report the results of a randomized, double-blind, phase
II trial (IUNO) that was conducted as a postapproval commitment
tudy, to prospectively determine the relative survival beneﬁt of
early’ maintenance erlotinib therapy (postchemotherapy, but prior
o progression) versus ‘late’ second-line erlotinib therapy (i.e. post-
rogression) in patients with advanced or metastatic NSCLC whose
umors did not harbor an EGFR-activating mutation (exon 19 dele-
ion or exon 21 L858R mutation) and who had not experienced
isease progression during four cycles of platinum-based therapy.
. Materials and methods
.1. Study design
IUNO was a randomized, double-blind, multicenter, placebo-
ontrolled phase III trial of maintenance erlotinib versus erlotinib
t the time of disease progression in patients with advanced
SCLC whose disease had not progressed following platinum-based
hemotherapy (ClinicalTrials.gov: NCT01328951; protocol number
O25460). Patients with known EGFR-activating mutations were
xcluded. The study was conducted in accordance with the princi-
les of the Declaration of Helsinki and Good Clinical Practice. All
atients provided written informed consent prior to any study-
elated procedures.
.2. Treatment and study endpoints
The study consisted of four phases: screening, blinded phase,
pen-label phase, and survival follow-up (Fig. 1). Patients were
creened into a chemotherapy run-in period and were required to
omplete four cycles of an approved noninvestigational platinum-
ased doublet chemotherapy without disease progression. Eligible
atients then entered the blinded phase in which they were ran-
omized 1:1 to receive maintenance erlotinib 150 mg/day orally
‘early erlotinib’) or placebo (‘late erlotinib’) until disease progres-
ion, death, or unacceptable toxicity. Patients who progressed on
lacebo during the blinded phase received erlotinib 150 mg/day
rally as an open-label second-line treatment until disease progres-
ion, death, or unacceptable toxicity. Patients who progressed on
rlotinib during the blinded phase received second-line treatment
ith an approved therapy (e.g. pemetrexed or docetaxel, but not
GFR-directed therapies) or best supportive care (BSC). All patients
ho completed the blinded and/or open-label study phases enteredhe survival follow-up phase, unless they withdrew consent for
urther study participation. Patients who experienced disease pro-
ression or unacceptable toxicity during the open-label phase could
eceive further lines of treatment or BSC. Patients who completeder 102 (2016) 30–37 31
the blinded phase but did not enter the open-label phase could
move directly into follow-up and receive BSC (but could still receive
further lines of treatment if considered appropriate at any time).
Randomization was stratiﬁed according to: histology
(squamous vs. nonsquamous); stage (IIIB vs. IV); response to
initial chemotherapy (complete response [CR]/partial response
[PR] vs. SD); inclusion of bevacizumab in the ﬁrst-line chemother-
apy run-in phase (yes vs. no); smoking status (current vs. former
vs. never); and geographical region.
The primary objective of the study was to compare overall sur-
vival (OS) with maintenance erlotinib versus second-line erlotinib.
Secondary objectives of the study were: to compare PFS, objective
response rate (ORR), and disease control rate (DCR) between the
study arms (erlotinib vs. placebo) during the blinded maintenance
phase; and to evaluate the safety and tolerability proﬁle of erlotinib
in this patient population.
2.3. Patients
Males or females aged ≥18 years with advanced/recurrent
(stage IIIB) or metastatic (stage IV) NSCLC who  had completed four
cycles of platinum-based chemotherapy without progression of
disease (end of last chemotherapy cycle ≤28 days prior to random-
ization) were eligible. Patients were required to have an Eastern
Cooperative Oncology Group performance status (ECOG PS) of 0 or
1.
Patients with known EGFR-activating mutations (exon 19 dele-
tion and exon 21 L858R mutations) determined by local testing
were excluded from the study. Patients with unknown EGFR-
mutation status or wild-type status determined by local testing
were screened and their tumor was tested in a central laboratory
(by cobas® EGFR test) to determine their EGFR-mutation status or
conﬁrm it as wild-type if locally assessed. Patients whose tumors
did not harbor an EGFR-activating mutation, or those with an
indeterminate EGFR-mutation status after central testing, were ran-
domized into the blinded phase of the study.
Prior exposure to EGFR inhibitors such as erlotinib, geﬁtinib,
or cetuximab, or prior chemotherapy or systemic antineoplastic
therapy for advanced disease before screening was not permit-
ted. Neither was  the use of pemetrexed in the maintenance setting
(pemetrexed was allowed during the chemotherapy run-in phase).
Additional exclusion criteria included: any other malignancies
within 5 years, except for curatively resected carcinoma in situ
of the cervix, basal or squamous cell skin cancer, ductal carci-
noma in situ, or organ-conﬁned prostate cancer; central nervous
system (CNS) metastases or spinal cord compression that had not
been deﬁnitely treated with surgery and/or radiation, or treated
CNS metastases or spinal cord compression without stable dis-
ease for ≥2 months; or any unstable systemic disease, metabolic
dysfunction, physical examination ﬁnding, or clinical laboratory
ﬁnding that contraindicated the use of study medication(s) or that
might have affected the interpretation of the results or rendered
the patient at high risk from treatment complications.
2.4. Statistical considerations
The primary efﬁcacy variable was OS, which was deﬁned as the
time from the date of randomization to the date of death, regardless
of the cause of death. OS was tested using a two-sided unstratiﬁed
log-rank test at a 5% signiﬁcance level. Median survival time was
estimated using Kaplan–Meier methodology. Hazard ratios and 95%
CIs were estimated by Cox proportional hazard regression. The pri-
mary efﬁcacy analysis was  planned when 460 events (deaths) had
been observed in 610 randomized patients (305 per treatment arm)
to ensure 80% power at a two-sided 5% signiﬁcance level to detect
a 30% improvement (HR, 0.77) in OS with maintenance erlotinib
32 S. Cicènas et al. / Lung Cancer 102 (2016) 30–37
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oFig. 1. Study design. BSC = best supportive care, EGFR = epidermal gro
median OS: 12.5 months) versus second-line erlotinib (median OS:
.6 months). The cut-off date for the primary analysis was March
3, 2015.
Secondary efﬁcacy variables were PFS, ORR, and DCR in the
aintenance setting. Disease progression in the blinded phase
as deﬁned according to Response Evaluation Criteria in Solid
umors (RECIST) version 1.1 [2]. Tumor assessments were sched-
led at baseline (within a maximum of 2 weeks before starting
rlotinib/placebo), Week 6, Week 12, Week 18, and then every 12
eeks until disease progression. Duration of PFS was  assessed dur-
ng the blinded phase of the study, and was deﬁned as the time from
andomization to disease progression or death, whichever occurred
rst.
Subgroup analyses compared OS and PFS in patient groups
eﬁned by stratiﬁcation factors, baseline demographics, and dis-
ase characteristics. Forest plots were used to display the HR, 95%
I, and median OS and PFS for each subgroup.
Safety was evaluated by recording and grading adverse events
AEs) in the blinded study phase according to National Can-
er Institute-Common Terminology Criteria for Adverse Events
NCI-CTCAE) version 4.0. Only serious AEs were collected in the
pen-label phase of the study and were evaluated separately. Inci-ctor receptor, NSCLC = non-small-cell lung cancer, PD = progressive disease.
dences of interstitial lung disease (ILD), an AE of special interest
with erlotinib, were also monitored.
All randomized patients were included in the intent-to-treat
(ITT) population to assess efﬁcacy endpoints, and all patients who
received at least one dose of study treatment were included in the
safety analysis population.
3. Results
3.1. Patients
Between September 6, 2011 and June 10, 2014, 1629 patients
were screened, of which 643 were randomized to receive main-
tenance erlotinib (n = 322) or placebo (n = 321) in the blinded
phase of the study (ITT population; Fig. 2). The most frequent
reasons for screening failure were: not completing four cycles
of platinum-based chemotherapy without progression of disease
(29.7%), death during these four cycles of chemotherapy (12.7%),
and identiﬁcation of patients whose tumors were found to har-
bor an EGFR-activating mutation after local testing at screening,
or via central testing after screening and prior to randomization
(13.0%). In total, 18 patients (5.6%) in the ‘early erlotinib’ arm and
S. Cicènas et al. / Lung Cancer 102 (2016) 30–37 33
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One patient each in the ‘early erlotinib’ and ‘late erlotinib’ arms were randomized 
SC = best supportive care, FU = follow-up, OLP = open-label phase, PD = progressive
3 patients (7.2%) in the ‘late erlotinib’ arm had an indeterminate
GFR-mutation status.
Two patients (one in each treatment arm) were excluded from
he safety analysis population due to not having received any dose
f study treatment. In addition, one patient who was  randomized
o the placebo arm received erlotinib during the blinded phase and
as therefore included in the erlotinib group for safety. The number
f patients included in the safety population was 322 and 319 in the
aintenance erlotinib and placebo groups, respectively.
Overall, 410 patients entered the open-label second-line phase
f the study: 160 patients (50%) from the maintenance erlotinib
‘early erlotinib’) arm and 250 patients (78%) from the ﬁrst-line
lacebo (‘late erlotinib’) arm (Fig. 2). Two patients who  were ran-
omized to the ‘late erlotinib’ arm received chemotherapy in the
pen-label phase of the study, even though they received placebo
n the blinded phase, and were therefore included in the second-
ine chemotherapy group for the open-label safety evaluation. The
umber of patients included in the open-label safety population
as 248 and 162 in the second-line erlotinib and chemotherapy
roups, respectively.
At data cut-off of March 23, 2015, a total of 84 patients (13%)
ere alive and in follow-up, and 10 patients (2%) were lost toollow-up (Fig. 2). Overall, 97 patients did not enter the survival
ollow-up phase. A total of 37 patients were still receiving treat-
ent: 22 in the blinded study phase and 15 in the open-labeld not receive study treatment.
e, SFU = survival follow-up.
second-line phase. In the survival follow-up phase, follow-up ther-
apy was  received by 85/321 patients (26.5%) in the ‘late erlotinib’
arm and 84/322 patients (26.1%) in the ‘early erlotinib’ arm; the
most common treatments were taxanes (17.1% vs. 8.7%, respec-
tively), antimetabolites (6.9% vs. 6.5%, respectively), and platinum
compounds (5.6% vs. 6.5%, respectively).
Baseline patient and demographic characteristics were balanced
between the study arms (Table 1). The median patient age was 61
years (range, 26–86) and most patients had stage IV, nonsquamous
disease.
3.2. Efﬁcacy
At the data cut-off date of March 23, 2015, 242 OS  events (75.2%)
had occurred in the ‘early erlotinib’ arm versus 235 events in the
‘late erlotinib’ arm (73.2%). Median OS was 9.7 months in patients
randomized to ‘early erlotinib’ and 9.5 months in patients ran-
domized to ‘late erlotinib’ (HR, 1.02, 95% CI: 0.85–1.22; log-rank
p = 0.82) (Fig. 3A). The 1-year OS rate was 42% in both treatment
arms. Results of subgroup analyses of OS according to strati-
ﬁcation factors, demographics, or baseline characteristics, were
generally consistent with those in the overall study population
(Supplementary Fig. 1). The HR for OS showed a trend in favor
of erlotinib maintenance over second-line erlotinib treatment in
female patients (HR, 0.78, 95% CI: 0.53–1.13), but no beneﬁt of
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Table 1
Patient baseline characteristics.
Characteristic Placebo
(n = 321)
Maintenance
erlotinib (n = 322)
Median age, years (range) 61 (30–86) 61 (26–81)
Male/Female, % 76/24 74/26
Stage IIIB/IV, % 22/78 22/78
White/Asian/Other, % 78/21/1 76/22/2
ECOG PS 0/1, % 29/71 28/72
Smoker, %
Current/Former/Never 57/27/16 58/25/17
Nonsquamous/Squamous, % 64/36 64/36
Response to prior chemotherapy, %
CR  + PR/SD 36/64 36/64
Region, %
Eastern Europe/South East Asia/Western Europe/Other 55/21/13/11 53/22/14/11
CR = complete response, ECOG PS = Eastern Cooperative Oncology Group performance status, PR = partial response, SD = stable disease.
Fig. 3. Kaplan−Meier estimates of (A) overall survival and (B) progression-free survival during the blinded study phase (ITT population).
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Table  2
Secondary efﬁcacy outcomes during the blinded study phase.
Parameter Placebo
(n = 321)
Maintenance
erlotinib (n = 322)
ORR
Responder (CR + PR), n (%) CR PR SD 12 (3.7)2 (0.6)10 (3.1)178 (55.5) 21 (6.5)3 (0.9)18 (5.6)176 (54.7)
Difference in response rate, % 2.78 (−0.78, 6.35)
P  value 0.11
DCR
Responder (CR + PR + SD), n (%) 190 (59.2) 197 (61.2)
Difference in response rate 1.99 (−5.74, 9.72)
C  parti
m
C
a
(
o
P
w
6
2
g
o
3
p
e
i
q
i
a
b
(
e
c
r
(
o
d
(
p
i
e
r
e
i
(
j
t
r
4
v
‘
m
O
l
EP  value 
R = complete response, DCR = disease control rate, ORR = overall response rate, PR =
aintenance erlotinib was seen in patients with SD (HR, 1.11, 95%
I: 0.88–1.39), although the study was not powered for subgroup
nalyses.
No meaningful differences were noted in PFS (Fig. 3B), ORR
Table 2), or DCR (Table 2) between the maintenance erlotinib
r placebo arms during the blinded phase of the trial. Median
FS was 13.0 weeks with maintenance erlotinib and 12.0 weeks
ith placebo (HR, 0.94, 95% CI: 0.80–1.11; log-rank p = 0.48). The
-month PFS rate was 24% (95% CI: 19.5–28.9) and 27% (95% CI:
2.2–32.0) in the placebo and erlotinib arms, respectively. Sub-
roup analyses of PFS were consistent with the results for the
verall study population (data not shown).
.3. Safety
During the blinded phase of the trial, 255 erlotinib-treated
atients (79.2%) and 181 placebo-treated patients (56.7%) experi-
nced at least one AE (Table 3). Most AEs were mild or moderate
n intensity. Rash (39.4%) and diarrhea (24.2%) were the most fre-
uently reported events with erlotinib. Serious AEs were reported
n 36 patients (11.2%) and 27 patients (8.5%) receiving erlotinib
nd placebo, respectively. Serious AEs resulting in death during the
linded phase occurred in 11 patients (3.4%) in the erlotinib group
three events of pulmonary embolism, two of pneumonia, and one
vent each of cardiopulmonary failure, cardiorespiratory arrest,
erebrovascular accident, metabolic acidosis, hemoptysis, and aspi-
ation pneumonia) and three patients (0.9%) in the placebo group
lobar pneumonia, hydrocephalus, and respiratory arrest). None
f these events was considered causally related to blinded study
rug. There were three occurrences of ILD or ILD-like events in two
0.6%) erlotinib-treated patients; although one of these patients had
reexisting ILD at baseline.
During the open-label study phase, 23 patients (9.3%) receiv-
ng erlotinib and eight patients (4.9%) receiving chemotherapy
xperienced a serious AE (Table 3). Related serious AEs were
eported in 11 patients (4.4%) and two patients (1.2%) receiving
rlotinib and chemotherapy, respectively. Serious AEs resulting
n death occurred in seven patients (2.8%) in the erlotinib group
pneumonia, aspirational pneumonia, hemoptysis, cardiac failure,
aundice, dyspnea, and unknown cause) and one patient (0.6%) in
he chemotherapy group (nosocomial pneumonia). There were no
eported cases of ILD in the open-label study phase.
. Discussion
The aim of the IUNO trial was to determine the relative sur-
ival beneﬁt of ‘early’ maintenance erlotinib treatment versus
late’ second-line erlotinib treatment in patients with advanced or
etastatic NSCLC with no known EGFR-activating mutations. No
S beneﬁt was observed for maintenance erlotinib versus second-
ine erlotinib treatment in patients with advanced NSCLC without
GFR-activating mutations. Subgroup analyses of OS based on strat-0.61
al response, SD = stable disease.
iﬁcation factors, demographics, or baseline characteristics were
consistent with the results for the overall population. In female
patients, the HR for OS showed a trend in favor of erlotinib mainte-
nance treatment over second-line erlotinib, but no beneﬁt was seen
in patients with SD at baseline. This latter result is in contrast to
ﬁndings of the SATURN study [1], but in-line with data from the ran-
domized phase III IFCT-GFPC 0502 trial of gemcitabine or erlotinib
maintenance therapy versus observation in patients with advanced
NSCLC, which also included a predeﬁned second-line therapy in the
control arm [3].
The discrepancy between the IUNO and SATURN study results
with respect to OS improvement may  partly be explained by the dif-
ference in the proportion of patients receiving second-line erlotinib
between the two trials; IUNO included second-line treatment with
erlotinib for 78% of patients on the ﬁrst-line placebo arm, while
in SATURN only 21% of patients on the placebo arm received
erlotinib as second-line treatment [1]. Furthermore, it is conceiv-
able that the lower sensitivity of the EGFR test used in SATURN
(Sanger sequencing) may  have played a role, together with the
fact that EGFR mutation status was indeterminate in 4% and 5% of
patients on the erlotinib and placebo arms, respectively, and was
missing in 12% of patients in each treatment arm [1]. The proportion
of patients with indeterminate EGFR mutation status after central
testing in IUNO was  low and comparable in both treatment arms
(5.6% in the ‘early erlotinib’ arm and 7.2% in the ‘late erlotinib’ arm).
PFS assessed during the blinded maintenance phase was not
superior in the erlotinib arm compared with the placebo arm. Sim-
ilarly, no ORR or DCR beneﬁt was  observed in the blinded phase
of the trial comparing erlotinib with placebo. Although the open-
label phase of the study was controlled for treatment allocation,
there was  an imbalance in the proportion of patients who  received
second-line chemotherapy following erlotinib maintenance (50%)
compared with those who  received second-line erlotinib follow-
ing placebo maintenance (78%). While the proportion of patients
receiving second-line chemotherapy is lower than expected, these
ﬁgures are comparable with other studies in this setting [1,4]. How-
ever, the reasons for not receiving second-line treatment were
not prospectively collected and may  have been inﬂuenced by the
fact that chemotherapy was  administered in accordance with local
practice and reimbursement, while erlotinib was supplied by the
Sponsor.
The PFS results in the maintenance phase of this study contrast
with the EGFR wild-type subgroup ﬁndings from the SATURN study,
which demonstrated a survival improvement with maintenance
erlotinib versus placebo in patients with wild-type EGFR status
[1,5]. In SATURN, the PFS analysis showed a HR of 0.78 (median 8.9
vs. 12.0 weeks; 95% CI: 0.63–0.96; p = 0.02) for the erlotinib group
relative to the placebo group, while the secondary endpoint of OS
showed a HR of 0.77 (median 10.2 months vs. 11.3 months, 95%
CI: 0.61–0.97; p = 0.02) [1,5]. A PFS beneﬁt was also reported with
maintenance erlotinib in the IFCT-GFPC 0502 trial, with a HR of 0.69
for the erlotinib group versus the observation group (median 2.9 vs.
36 S. Cicènas et al. / Lung Cancer 102 (2016) 30–37
Table 3
Safety summary during the blinded and open-label study phases.
Blinded phase n, (%) Placebo
(n = 319)
Maintenance
erlotinib (n = 322)
Patients with at least one AE 181 (56.7) 255 (79.2)
Total  number of AEs 604 962
Patients with at least one:
AE with fatal outcome 3 (0.9) 11 (3.4)
Serious  AE 27 (8.5) 36 (11.2)
Related AE 47 (14.7) 204 (63.4)
Related serious AE 2 (0.6) 6 (1.9)
Grade  3–5 AE 49 (15.4) 77 (23.9)
AE  leading to withdrawal from treatment 3 (0.9) 10 (3.1)
AE  leading to dose modiﬁcation/interruption 12 (3.8) 45 (14.0)
AE  of special interest (ILD) 0 2 (0.6)
Open-label phase n, (%) Second-line chemotherapy
(n = 162)
Second-line
erlotinib (n = 248)
Patients with at least one serious AE 8 (4.9) 23 (9.3)
Total  number of serious AEs 12 31
Patients with at least one:
Serious AE with fatal outcome 1 (0.6) 7 (2.8)
Related serious AE 2 (1.2) 11 (4.4)
Serious  AE leading to withdrawal from treatment 1 (0.6) 2 (0.8)
Serious AE leading to dose modiﬁcation/interruption 3 (1.9) 8 (3.2)
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.9 months, 95% CI: 0.54–0.88; p = 0.03), however, the study was
ot exclusively conducted in patients with EGFR wild-type tumors
nd included a small number of patients with EGFR mutations [3].
he reasons for the lack of PFS beneﬁt with maintenance erlotinib
ersus placebo in the IUNO study are unclear, but this study demon-
trated that there is no discernible maintenance treatment effect
n patients with EGFR wild-type tumors for inhibition of EGFR by
rlotinib when patients have a response or disease control after
dministration of ﬁrst-line chemotherapy.
Extrapolation of the blinded phase maintenance results from
he IUNO study to treatment in other settings cannot be made.
t is important to note that the impact of treatment for patients
ho have not progressed following chemotherapy (maintenance)
ay  differ from the impact of treatment for patients whose disease
s actively progressing (second-line). In addition, although there
as an active control in the second-line open-label phase of the
UNO study, no conclusions can be drawn as the study was not
esigned to comparatively evaluate erlotinib versus chemother-
py in the second-line setting, there was a noticeable imbalance in
reatment received, and there was no randomization. The pivotal
R.21 study in patients with stage IIIB/IV NSCLC supports the efﬁ-
acy and clinical beneﬁt of erlotinib over placebo in the second-line
etting, irrespective of EGFR-mutation status [6].
Erlotinib was generally well tolerated in the current trial and
o new safety signals were identiﬁed. Safety results in erlotinib-
reated patients were consistent with the safety proﬁle established
n previous clinical trials [7,8] and similar to those obtained in the
ATURN study [1]. Eleven patients who received ‘early erlotinib’
uring the blinded phase died during the maintenance phase due
o an AE compared with three patients who received placebo. None
f these events were considered causally related to blinded study
rug, but instead were considered related to NSCLC or concurrent
onditions. Additionally, most patients had multiple risk factors
ncluding relevant comorbidities, smoking, and/or were taking con-
omitant medications, which may  have contributed to the events
bserved.In summary, based on the lack of beneﬁt observed in this trial,
he use of maintenance treatment with erlotinib in patients with
dvanced or metastatic NSCLC without EGFR-activating mutations
s no longer considered to be favorable. The beneﬁt of ﬁrst-linetreatment with erlotinib in patients with advanced NSCLC whose
tumors harbor EGFR-activating mutations is well established. An
improvement in PFS was  observed also in the maintenance set-
ting with erlotinib versus placebo in the SATURN study overall and
in the EGFR mutation-positive subgroup [1]. In light of the results
of the IUNO study, the maintenance indication is being revised,
and maintenance therapy with erlotinib should only be consid-
ered for patients with locally advanced or metastatic NSCLC with
EGFR-activating mutations.
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